Supriya Lifescience P/FCF

Mitä Supriya Lifescience tekee? Supriya Lifescience Ltd is a pharmaceutical company based in Mumbai, India, operating within the healthcare sector. The company specializes in the research, development, and manufacturing of active pharmaceutical ingredients (APIs), with a focus on niche therapeutic segments. It employs 392 full-time staff and completed its initial public offering (IPO) on December 28, 2021. The firm's manufacturing facilities are located in Maharashtra, and it exports products to approximately 86 countries. Its product portfolio includes APIs for antihistamines, anesthetics, anti-asthma treatments, and other therapeutic areas such as analgesics and vitamins. Specific products mentioned include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulphate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride. The company is engaged in the production of bulk drugs and pharmaceutical chemicals, serving global markets through its export activities. It operates with a focus on niche API products, addressing specific therapeutic needs across multiple categories. The company's website is https://supriyalifescience.com/. Supriya Lifescience on yksi Eurpooliin suosituimmista yhtiöistä.